Steven Burnett, MD
Dermatology · Sarasota, FLNPI 1063590149
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,000 of the $5,315 with a category attached, or 75.3%. Aclaris Therapeutics, Inc. accounts for 94.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $5,039 and has fallen 95.8% since, to $213 in 2024.
Across 20 payments — averaging $265.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aclaris Therapeutics, Inc.$5K
- Organogenesis Inc.$62
- Elekta, Inc.$35
- Boehringer Ingelheim$33
- AbbVie$28
- Convatec Inc.$26
- plus $93 from 5 others
What the payments were for
- Consulting fees$4,00075%
- Travel & lodging$73914%
- Food & beverage$57611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aclaris Therapeutics, Inc. | 9 | $5,039 |
| Organogenesis Inc. | 2 | $62 |
| Elekta, Inc. | 1 | $35 |
| Boehringer Ingelheim | 1 | $33 |
| AbbVie | 1 | $28 |
| Convatec Inc. | 1 | $26 |
| Merz North America, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Strata Skin Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ESKATA$4,842
How this compares
$5,315 in reported general payments places this provider in the 65th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 92 | $5,474 |
| Desonide | 28 | $2,598 |
| Fluocinolone Acetonide | 29 | $2,277 |
| Cephalexin | 440 | $2,018 |
| Triamcinolone Acetonide | 116 | $1,169 |
| Hydrocortisone | 106 | $1,155 |
| Betamethasone Dipropionate | 36 | $990 |
| Mupirocin | 124 | $906 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 15 | $862 |
| Ketoconazole | 65 | $835 |
| Doxycycline Monohydrate | 81 | $805 |
| ValacyclovirValacyclovir Hcl | 36 | $436 |
| Halobetasol Propionate | 11 | $248 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Sarasota
- Robert FinkelsteinSarasota$421K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.